
Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.
Professor Matthias Augustin details the various clinical manifestations of prurigo nodularis, illustrating how different lesion types can present concurrently in patients.
Professors Matthias Augustin and Sarina Elmariah evaluate how targeted therapies transform the management of prurigo nodularis, addressing the itch-scratch cycle and broader manifestations such as lesions.

Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
Professor Sarina Elmariah describes how IL-4 and IL-13, key drivers of type 2 inflammation, uniquely contribute to manifestations of prurigo nodularis beyond itch.

Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
Join ADVENT for an educational symposium on PN at WCI 2025!